Pancreatic Cancer Research

ResearcherHong Kong Baptist UniversityActive in the last 2 years

Aiping Lü

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2303-0494; OpenAlex author ID A5076594495. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 4 papers · 2025: 1 paper · 2026: 3 papers

Papers 12

  1. 5'-NucA-SMCC-DM1 and 5'-NucA-SPDMV-DM1 are Potent Aptamer-Drug Conjugates against Pancreatic Cancer. Co-author DOI 10.1021/acsomega.5c11364↗
  2. Isoliquiritigenin from Licorice Attenuates Metastatic Development of Pancreatic Cancer by Regulation of Selective Autophagy-Mediated Ferroptosis and the Tumor … Co-author DOI 10.1142/s0192415x26500710↗
  3. Nuclear uPA as a transcription regulator in parenchymal cells promotes Schwann cell-mediated perineural invasion in pancreatic ductal adenocarcinoma Co-author DOI 10.21203/rs.3.rs-9820104/v1↗
  4. The supporting role of Schwann cells in perineural invasion of pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fphar.2025.1540027↗
  5. Exploring fructose metabolism as a potential therapeutic approach for pancreatic cancer. Co-author DOI 10.1038/s41418-024-01394-3↗
  6. Insights and therapeutic advances in pancreatic cancer: the role of electron microscopy in decoding the tumor microenvironment. Co-author DOI 10.3389/fcell.2024.1460544↗
  7. Therapeutic potential of flavonoids from traditional Chinese medicine in pancreatic cancer treatment. Co-author DOI 10.3389/fnut.2024.1477140↗
  8. Inflammatory Processes: Key Mediators of Oncogenesis and Progression in Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.3390/ijms252010991↗
  9. Mechanistic Insights into the Roles of the IL-17/IL-17R Families in Pancreatic Cancer. Co-author DOI 10.3390/ijms241713539↗
  10. Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy. Co-author DOI 10.3389/fcell.2022.855474↗
  11. Effect of the Natural Product Triptolide on Pancreatic Cancer: A Systematic Review of Preclinical Studies. Last author DOI 10.3389/fphar.2017.00490↗
  12. Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine. Last author DOI 10.18632/oncotarget.7073↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fangfei Li · 4 shared papers, 2022–2024 · strength 0.92
  2. Kenneth C. P. Cheung · 3 shared papers, 2024–2026 · strength 0.79
  3. Hong Dai · 2 shared papers, 2024–2026 · strength 0.60
  4. Fangfei Li · 2 shared papers, 2025–2026 · strength 0.53
  5. Yun He · 2 shared papers, 2025–2026 · strength 0.53
  6. Ge Zhang · 2 shared papers, 2022–2024 · strength 0.45
  7. Zhu Zhang · 1 shared paper, 2026 · strength 0.32
  8. Joshua Ka-Shun Ko · 1 shared paper, 2026 · strength 0.32
  9. Yang Liu · 1 shared paper, 2024 · strength 0.28
  10. Qi Wan · 1 shared paper, 2024 · strength 0.26
  11. Zhaoliang Su · 1 shared paper, 2025 · strength 0.24
  12. Fadian Ding · 1 shared paper, 2025 · strength 0.24
  13. Zhen Chen · 1 shared paper, 2023 · strength 0.20
  14. Wei Ping Jia · 1 shared paper, 2024 · strength 0.20
  15. Chengqiang Wang · 1 shared paper, 2024 · strength 0.20
  16. Xiaoqiu Wu · 1 shared paper, 2022 · strength 0.17
  17. Hong Dai · 1 shared paper, 2022 · strength 0.17
  18. Chi Zhang · 1 shared paper, 2017 · strength 0.09
  19. Hongxia Li · 1 shared paper, 2016 · strength 0.06
  20. Cheng Wang · 1 shared paper, 2016 · strength 0.06
  21. Xuelian Xu · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.